Siglec signaling may act in concert with other immunomodulatory features of tolDCs, including expression of MHC and other risk genes predisposing to T1D, production of suppressive cytokines and expression of immune-evasive defensins (e.g., cathelicidin) [28,30,31,32,33,34,35]. This evidence concerns the gene HLA-C and type 1 diabetes mellitus.